In pulmonary arterial hypertension lung samples researchers have observed elevated asporin levels and found a link between these levels and lower disease severity. Higher levels of asporin appeared to counteract the pathological remodeling of the pulmonary vasculature that characterizes pulmonary arterial hypertension.
Jason Hong, MD, PhD, assistant clinical professor at David Geffen School of Medicine at University of California, Los Angeles, is the first author of the study, published in Circulation titled “Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension”
In an interview with Healio news Hong describes the study and suggests that targeting asporin, or enhancing its activity, could provide a new strategy for slowing or reversing the progression of pulmonary arterial hypertension.
Read more at this link on the Healio web page